Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mirtazapine→

Mirtazapine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
85650-52-8
Molecular formula
C17H19N3
Molecular weight
265.35 g/mol
Drug class
Tetracyclic antidepressantnoradrenergic and specific serotonergic antidepressant (NaSSA)
Mechanism of action
The mechanism in major depressive disorder is not fully understood. Mirtazapine antagonises central presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, potentially increasing noradrenergic and serotonergic neurotransmission; it also antagonises 5-HT2, 5-HT3 and H1 receptors.
Indications / reported uses
  • Treatment of major depressive disorder in adults; the exact contribution of noradrenergic and serotonergic actions to clinical response is not fully established

Sources: NLM DailyMed — Mirtazapine tablets, label updated 25 June 2025 · NLM MeSH — Mirtazapine · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Tetracyclic antidepressant; noradrenergic and specific serotonergic antidepressant (NaSSA)

Mechanism of action

The mechanism in major depressive disorder is not fully understood. Mirtazapine antagonises central presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, potentially increasing noradrenergic and serotonergic neurotransmission; it also antagonises 5-HT2, 5-HT3 and H1 receptors.

General use cases

  • Treatment of major depressive disorder in adults; the exact contribution of noradrenergic and serotonergic actions to clinical response is not fully established

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Mirtazapine Environmental Risk Assessment (ERA) (the Mirtazapine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.